About Us

We're Making History

Celebrating Nearly 30 Years of Performance
Explore Anika’s Milestones

Anika acquires Arthrosurface, a leading, privately-held provider of joint surface and preservation solutions for active patients, and Parcus Medical, a leading, privately-held sports medicine company.


Anika launches TACTOSET®, a surgically-delivered therapy for bone repair procedures.

Anika completes the implementation of a U.S.-based hybrid commercial model through which the Company launches TACTOSET®.

MONOVISC® and ORTHOVISC® become the #1 prescribed viscosupplement franchise in the United States.

Anika expanded its executive leadership team through a CEO transition with key hires to promote sales growth and drive operational efficiency.


Anika celebrates its 25th anniversary.

Anika inaugurates its newly expanded and consolidated state-of-the-art facility to manufacture and package the totality of the company’s diverse portfolio in Bedford, Massachusetts.

Anika completes enrollment in second pivotal Phase III Trial of CINGAL® for the treatment of knee pain associated with osteoarthritis.

Anika receives FDA 510(k) clearance for TACTOSET®, a surgically-delivered therapy for bone repair procedures.

Anika wins CE Mark approval for CINGAL®, a formulation of HA plus a steroid for the treatment of osteoarthritis.

Anika receives CE Mark approval for ORTHOVISC®-T, a treatment indicated to relieve pain and restore function in tendons affected by chronic lateral epicondylosis.


Anika receives Health Canada approval for CINGAL®.

Starts trial enrollment for FastTRACK Phase III HYALOFAST® clinical study.

Files investigational device exemption to initiate phase III study to expand the indication of MONOVISC® to treat pain caused by osteoarthritis of the hip.

Anika is ranked #90 on Fortune’s Fastest Growing Companies for 2015.

Anika receives FDA approval to commercialize MONOVISC® in the United States.

Completes trial enrollment for CINGAL®.

Reaches an agreement with Medline Industries, Inc., a world-leading wound care company, for the United States commercialization of HYALOMATRIX®, our leading advanced wound care product.

Anika receives a unique reimbursement code for MONOVISC® effective January 1, 2015 simplifying the reimbursement process and improving patient access.


ORTHOVISC® achieves #1 U.S. market leader position in the multi-injection viscosupplement market.

Anika begins its first full-operation year in a new state-of-the-art pharmaceutical facility in Bedford, MA, USA with expanded capacity and efficiency.

Completes strategic acquisition of Anika Therapeutics S.r.l., a now wholly owned subsidiary by Anika Therapeutics, Inc. based in Padova, Italy.


Anika launches ORTHOVISC® mini, a line extension to treat osteoarthritis symptoms in small joints such as the hands and jaw.

Anika begins commercialization of MONOVISC® in Europe.

Anika receives approval to market MONOVISC® in Europe. Today, MONOVISC® is available in most countries in Europe through an experienced distributor base.

Anika relocates its corporate facilities and research & development laboratories to expand and enhance the company’s product development and manufacturing capabilities.


Anika receives a unique reimbursement code for ORTHOVISC® effective January 1, 2007 simplifying the reimbursement process and improving patient access.

Anika receives FDA approval and launches ORTHOVISC® in the United States.


Anika establishes a marketing and distribution relationship with Ortho Biotech Products, L.P., a subsidiary of Johnson & Johnson to market ORTHOVISC® in the United States once approved by the FDA.

Anika begins commercialization of its osteoarthritis product, ORTHOVISC®, in Canada.


Anika receives CE Mark approval for ORTHOVISC® for the treatment of the symptoms of osteoarthritis in humans.

The company signs a three-year exclusive distribution agreement with Boehringer Ingelheim Animal Health for its equine osteoarthritis product, HYVISC®.


Anika is incorporated as a spin-off of MedChem Products, Inc.

Anika signs an extension agreement with IOLAB, a Johnson & Johnson subsidiary, to enter into a five-year manufacturing contract for its ophthalmic products, AMVISC® and AMVISC® PLUS. This partnership lasted for 22 years, ending in 2014.